Tag Archives: ivermectin

NIH Revises Use of Ivermectin for Fight Against COVID-19

There have been various reports regarding the use of Ivermectin in the fight to treat COVID-19. I had posted about local COVID-19 fighter, Dr. Joseph Varon, and his associates’ effort to have the federal government recognize the use of the anti-parasitic drug in treating COVID-19. A slight change in attitude has occured at the federal level.

While the feds were upscaling their efforts in creating vaccines for COVID-19, there was still a worry that lack of availability of the vaccine would not help efforts to fight the actual infections that were still occurring in real-time. Dr. Varon and his associates were among various scientists studying the use of Ivermectin, which was known to be used in fighting worms in dogs, but approved for human use for over 40 years. Considering the botched roll-out by Trump and Texas Governor Abbott, this is quite timely as infections and hospitalizations continue to overtax local resources.

Medical authorities at the federal level had taken the attitude that, while Ivermectin was FDA-approved, it was not approved for use against COVID-19. Recent reports state that the National Institutes of Health has changed course.

One week after Dr. Paul Marik and Dr. Pierre Kory—founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC)— along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation on ivermectin, making it an option for use in COVID-19. 

This new designation upgraded the status of ivermectin from “against” to “neither for nor against”, which is the same recommendation given to monoclonal antibodies and convalescent plasma, both widely used across the nation. 

By no longer recommending against ivermectin use, doctors should feel more open in prescribing ivermectin as another therapeutic option for the treatment of COVID-19. This may clear its path towards FDA emergency use approval. 

“Ivermectin is one of the world’s safest, cheapest and most widely available drugs,” noted Dr. Kory, President of the FLCCC Alliance. “The studies we presented to the NIH revealed high levels of statistical significance showing large magnitude benefit in transmission rates, need for hospitalization, and death. What’s more, the totality of trials data supporting ivermectin is without precedent.”

Newswise.com 1/15/2021

Dr. Marek and Dr. Kory were among those scientists working with Dr. Varon.

This is great news as studies have found that Ivermectin can be used post-exposure, early-stage, and even during late stage. The drug has anti-viral and anti-inflammatory properties which have helped numerous patients locally.

Here’s a link to DosCentavos’ post regarding Dr. Varon’s press conference on Ivermectin.

The vax roll-out is now in the hands of the Biden administration, which has had to get to the bottom of Trump’s failures. While the roll-out continues, we must continue to mask-up, wash hands, social distance, and if possible stay away from humans outside of one’s immediate family. And, in case you haven’t heard…double mask!

Varon, FLCCC: A COVID-19 Treatment That Must Be Approved Now

Dr. Joseph Varon, of Houston’s United Memorial Medical Center, and a team of researchers/physicians/ICU Specialists who have been working on COVID-19 patients, held a press conference last week regarding the treatment and even prevention of COVID-19 through a protocol developed through their own research.

According to Varon, one medication that has been effective in treating COVID-19 is Ivermectin. This drug has been around for over 40 years to treat parasitic infections and it’s affordable. Varon states that Ivermectin has been used as part of the I-MASK protocol to treat patients who are post-exposure, early stage, and even late stage, with some success and safety. A major find is that the drug is also preventative. The drug is not only anti-viral, but also anti-inflammatory.

The press conference was more of a call to action to request medical authorities at the federal and global level to study and authorize this treatment, and to update protocols of treatment, which has not occurred since August, 2020. In fact, it was in August that the FDA authorized Ivermectin for clinical trials. With the data already collected, they feel it is time to update the treatment protocols.

According to Dr. Pierre Kory of St. Luke’s in Wisconsin, multiple studies have shown decreases in mortality and positive treatment outcomes. As a prophylactic, it has been successful in preventing COVID-19. He states that lives are being saved.

Dr. Varon stated at various points that the group of physicians are in no way affiliated with the drug companies and that they have no conflicts of interest in supporting this method of treating and preventing COVID-19.

Professor of Medicine Dr. Paul Marik offered a global call to action for health authorities to look at the clinical trial data on Ivermectin, validate the data, and push for its use as we reach a critical point in the pandemic in which better treatments are needed. Marik stated quite emotively, “We must act now, we must act with conviction, and we must act with compassion.” Federal leadership has so far ignored the request.

Dr. Marik also pointed to clinical outcomes and benefits of various medications utilized and debated about, including Hydrocloroquine, Remdesivir, and others. They found that only Ivermectin had benefits for pre-exposure, post-exposure, and pulmonary/inflammatory/hospitalization phases of COVID-19.

Dr. Varon added that medical providers are tired of the death and destruction by COVID-19 and they have developed this treatment to not only help patients, but to help medical providers. When asked regarding competition with the billions of dollars already invested in vaccine development, Varon offered a dose of reality: 60% of the world will need to be vaccinated to reach some level of immunity and he has heard from his own patients and others that they are not willing or trusting of the vaccine enough to take it. What FLCCC offers is an alternative, as well as a way proven through their own research, to address COVID-19 now to compliment the vaccination process. As Dr, Marik put it, “It’s not a competition.”

Watch the press conference here, which includes Q&A with media for more information. One can also go to the FLCCC website to read the studies and other pertinent information. Here is the press kit that was also provided.